These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 23668663)
1. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. Paula-Lima AC; Brito-Moreira J; Ferreira ST J Neurochem; 2013 Jul; 126(2):191-202. PubMed ID: 23668663 [TBL] [Abstract][Full Text] [Related]
2. Post-synaptic scaffolding protein interactions with glutamate receptors in synaptic dysfunction and Alzheimer's disease. Proctor DT; Coulson EJ; Dodd PR Prog Neurobiol; 2011 Apr; 93(4):509-21. PubMed ID: 21382433 [TBL] [Abstract][Full Text] [Related]
3. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Viola KL; Klein WL Acta Neuropathol; 2015 Feb; 129(2):183-206. PubMed ID: 25604547 [TBL] [Abstract][Full Text] [Related]
4. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors. Mota SI; Ferreira IL; Rego AC Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316 [TBL] [Abstract][Full Text] [Related]
5. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Shemer I; Holmgren C; Min R; Fülöp L; Zilberter M; Sousa KM; Farkas T; Härtig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T Eur J Neurosci; 2006 Apr; 23(8):2035-47. PubMed ID: 16630051 [TBL] [Abstract][Full Text] [Related]
6. Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease. Bordji K; Becerril-Ortega J; Buisson A Rev Neurosci; 2011; 22(3):285-94. PubMed ID: 21568789 [TBL] [Abstract][Full Text] [Related]
7. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. Decker H; Jürgensen S; Adrover MF; Brito-Moreira J; Bomfim TR; Klein WL; Epstein AL; De Felice FG; Jerusalinsky D; Ferreira ST J Neurochem; 2010 Dec; 115(6):1520-9. PubMed ID: 20950339 [TBL] [Abstract][Full Text] [Related]
8. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. Louzada PR; Paula Lima AC; Mendonca-Silva DL; Noël F; De Mello FG; Ferreira ST FASEB J; 2004 Mar; 18(3):511-8. PubMed ID: 15003996 [TBL] [Abstract][Full Text] [Related]
9. Effect of Aβ Oligomers on Neuronal APP Triggers a Vicious Cycle Leading to the Propagation of Synaptic Plasticity Alterations to Healthy Neurons. Rolland M; Powell R; Jacquier-Sarlin M; Boisseau S; Reynaud-Dulaurier R; Martinez-Hernandez J; André L; Borel E; Buisson A; Lanté F J Neurosci; 2020 Jul; 40(27):5161-5176. PubMed ID: 32444385 [TBL] [Abstract][Full Text] [Related]
10. Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-β peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. Kervern M; Angeli A; Nicole O; Léveillé F; Parent B; Villette V; Buisson A; Dutar P J Alzheimers Dis; 2012; 32(1):183-96. PubMed ID: 22785392 [TBL] [Abstract][Full Text] [Related]
11. Interaction of amyloid-β (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice. Brito-Moreira J; Lourenco MV; Oliveira MM; Ribeiro FC; Ledo JH; Diniz LP; Vital JFS; Magdesian MH; Melo HM; Barros-Aragão F; de Souza JM; Alves-Leon SV; Gomes FCA; Clarke JR; Figueiredo CP; De Felice FG; Ferreira ST J Biol Chem; 2017 May; 292(18):7327-7337. PubMed ID: 28283575 [TBL] [Abstract][Full Text] [Related]
13. [Alzheimer's disease, amyloid peptide and synaptic dysfunction]. Hémar A; Mulle C Med Sci (Paris); 2011; 27(8-9):733-6. PubMed ID: 21880261 [TBL] [Abstract][Full Text] [Related]
14. Amyloid-β oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: Relevance to the synapse pathology of Alzheimer's disease. Taniguchi K; Yamamoto F; Amano A; Tamaoka A; Sanjo N; Yokota T; Kametani F; Araki W Neurosci Res; 2022 Jul; 180():90-98. PubMed ID: 35257837 [TBL] [Abstract][Full Text] [Related]
15. Amyloid beta peptides and glutamatergic synaptic dysregulation. Parameshwaran K; Dhanasekaran M; Suppiramaniam V Exp Neurol; 2008 Mar; 210(1):7-13. PubMed ID: 18053990 [TBL] [Abstract][Full Text] [Related]
16. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. Tu S; Okamoto S; Lipton SA; Xu H Mol Neurodegener; 2014 Nov; 9():48. PubMed ID: 25394486 [TBL] [Abstract][Full Text] [Related]
17. Role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease. Cheng X; Wu J; Geng M; Xiong J Neurobiol Aging; 2014 Jun; 35(6):1217-32. PubMed ID: 24368087 [TBL] [Abstract][Full Text] [Related]
18. Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers. Jürgensen S; Antonio LL; Mussi GE; Brito-Moreira J; Bomfim TR; De Felice FG; Garrido-Sanabria ER; Cavalheiro ÉA; Ferreira ST J Biol Chem; 2011 Feb; 286(5):3270-6. PubMed ID: 21115476 [TBL] [Abstract][Full Text] [Related]
19. Synaptic dysfunction in Alzheimer's disease. Marcello E; Epis R; Saraceno C; Di Luca M Adv Exp Med Biol; 2012; 970():573-601. PubMed ID: 22351073 [TBL] [Abstract][Full Text] [Related]
20. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Alberdi E; Sánchez-Gómez MV; Cavaliere F; Pérez-Samartín A; Zugaza JL; Trullas R; Domercq M; Matute C Cell Calcium; 2010 Mar; 47(3):264-72. PubMed ID: 20061018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]